医药与保健
醫藥與保健
의약여보건
MEDICINE AND HEALTH CARE
2014年
8期
70-71
,共2页
心室重塑%慢性心力衰竭%美托洛尔
心室重塑%慢性心力衰竭%美託洛爾
심실중소%만성심력쇠갈%미탁락이
Metoprolol ventricular remodeling%chronic heart failure%metoprolol
目的：评估美托洛尔对慢性充血性心力衰竭（CHF）的临床疗效。方法将96例由于不同病因所致的心力衰竭患者随机分成两组，对照组48例，治疗组48例；心功能分级Ⅰ-Ⅳ级（按NYHA分级）。对照组仅给予常规抗心衰药物（如利尿剂、硝酸酯类、洋地黄、ACEI、心酰胺）治疗，治疗组在常规治疗的基础上加用小剂量美托洛尔，并逐步加大剂量治疗6个月，疗程结束后，对两组治疗前后的临床症状及心功能分级改善情况进行对比。结果治疗组临床症状改善情况明显优于对照组，差异有统计学意义（P＜0.05）；与对照组比较，治疗组心脏指数（CI）、心搏量（CO）、射血分数EF、VVS、LV等均有显著改善（P＜0.05）；但两组心功能分级改善情况差异不明显（P＞0.05）。结论在常规治疗基础上加用美托洛尔对慢性充血性心力衰竭安全有效，不仅能显著抑制心室重塑发展，降低患者死亡率，长期应用还能有效改善患者预后（疗程＞半年）。
目的：評估美託洛爾對慢性充血性心力衰竭（CHF）的臨床療效。方法將96例由于不同病因所緻的心力衰竭患者隨機分成兩組，對照組48例，治療組48例；心功能分級Ⅰ-Ⅳ級（按NYHA分級）。對照組僅給予常規抗心衰藥物（如利尿劑、硝痠酯類、洋地黃、ACEI、心酰胺）治療，治療組在常規治療的基礎上加用小劑量美託洛爾，併逐步加大劑量治療6箇月，療程結束後，對兩組治療前後的臨床癥狀及心功能分級改善情況進行對比。結果治療組臨床癥狀改善情況明顯優于對照組，差異有統計學意義（P＜0.05）；與對照組比較，治療組心髒指數（CI）、心搏量（CO）、射血分數EF、VVS、LV等均有顯著改善（P＜0.05）；但兩組心功能分級改善情況差異不明顯（P＞0.05）。結論在常規治療基礎上加用美託洛爾對慢性充血性心力衰竭安全有效，不僅能顯著抑製心室重塑髮展，降低患者死亡率，長期應用還能有效改善患者預後（療程＞半年）。
목적：평고미탁락이대만성충혈성심력쇠갈（CHF）적림상료효。방법장96례유우불동병인소치적심력쇠갈환자수궤분성량조，대조조48례，치료조48례；심공능분급Ⅰ-Ⅳ급（안NYHA분급）。대조조부급여상규항심쇠약물（여이뇨제、초산지류、양지황、ACEI、심선알）치료，치료조재상규치료적기출상가용소제량미탁락이，병축보가대제량치료6개월，료정결속후，대량조치료전후적림상증상급심공능분급개선정황진행대비。결과치료조림상증상개선정황명현우우대조조，차이유통계학의의（P＜0.05）；여대조조비교，치료조심장지수（CI）、심박량（CO）、사혈분수EF、VVS、LV등균유현저개선（P＜0.05）；단량조심공능분급개선정황차이불명현（P＞0.05）。결론재상규치료기출상가용미탁락이대만성충혈성심력쇠갈안전유효，불부능현저억제심실중소발전，강저환자사망솔，장기응용환능유효개선환자예후（료정＞반년）。
Objective To evaluate the clinical efficacy of metoprolol on chronic congestive heart failure (CHF).Method 96 patients with heart failure caused by different causes can be divided into two groups:treatment group (48 cases and control group 48 cases;Heart function class Ⅰ-Ⅳ (according to the NYHA classification) two groups of patients were given routine heart failure treatment, diuretics,ACE), digitalis,amide,nitrate),treatment group with small dose of metoprolol,and gradually increase the dose of treatment for 6 months,after the treatment,compared two groups before and after treatment of clinical symptoms and improve cardiac function classification.Result (1) Clinical symptoms improved in treatment group is better than that of control group,P<0.05).The treatment group cardiac index (CI),stroke volume (CO)、ejection fraction、EF、VVS、LVD were significantly improved (P<0.05) as compared with the control group;but the difference of cardiac function classification is not significantly (P>0.05).Conclusion On the basis of conventional treatment combined with metoprolol on chronic congestive heart failure is safe and effective,effectively inhibit development of ventricular remodeling,significantly reduce the mortality of patients,long-term treatment can obviously improve the prognosis of patients with heart failure (course>half a year).
